Of the CD200 positive cases; 12/40 (30.0%) were categorized as intermediate risk MDS and 15/17 (88.2%) were categorized as high risk MDS and the differences were statistically significant (P<0.001) (Table 2). This evidence concerns the gene CD200 and myelodysplastic syndrome.